MedTrace Logo

A Study to Evaluate Safety and Efficacy of DC-TAB in Multiple Sclerosis

NCT02442570 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 32

Last updated 2015-08-27

No results posted yet for this study

Summary

The purpose of this study is to evaluate safety and clinical efficacy of DC-TAB in multiple sclerosis.

Conditions

Interventions

BIOLOGICAL

recombinant human alpha B-crystallin

intravenous injections

OTHER

Placebo comparator

intravenous injection

Sponsors & Collaborators

  • Delta Crystallon BV

    lead INDUSTRY

Principal Investigators

  • Lilly Boneva, MSc · Population Services International

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-09-30
Primary Completion
2014-06-30
Completion
2015-02-28

Countries

  • Bulgaria

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02442570 on ClinicalTrials.gov